NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals has amended its two RNAi collaboration agreements with Merck and consolidated them into a single collaboration, Alnylam said today.
 
The amendments focus on the nine new therapeutic targets that Merck will name at a later date. These new programs are in addition to the existing collaboration on NOGO pathway for spinal cord injury treatments.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.